MedPharm, a Guildford, UK-based topical and transdermal Contract Development and Manufacturing Organization (CDMO) and Ampersand Capital Partners portfolio company, announced a merger with Tergus Pharma, a Research Triangle Park, NC-based end-to-end contract service provider and a Great Point Partners portfolio company.
The combined organization will operate under the MedPharm name, establishing an end-to-end CDMO with scientific, clinical trial manufacturing and commercial production capabilities.
As part of this transaction, Tergus Pharma CEO Michael Kane has been appointed CEO of MedPharm while Patrick Walsh will continue to serve as Executive Chairman of MedPharm.
The merged business is positioned as a player in delivering a full suite of drug development and manufacturing services to innovators of all sizes focused on advancing topical and transepithelial pharmaceuticals. The strategic combination of Tergus and MedPharm’s capabilities enables commercial production and serialization to existing formulation development, in vitro testing and clinical manufacturing within one integrated organization. Expanded capabilities will also include the development and manufacture of hormone-based and highly potent drugs at the company’s GMP manufacturing facility in Durham, NC.
Tergus lead investor Great Point Partners will retain a significant minority ownership stake in the newly combined MedPharm, while private equity firms Ampersand Capital Partners and Bourne Partners Strategic Capital assume majority ownership.
FinSMEs
08/07/2024